Skip to main content
🦴RHEUMATOLOGY

Autoimmune & Rheumatic Disease

Lupus, rheumatoid arthritis, scleroderma β€” from lifelong immunosuppression to drug-free immune reset

~5 million people worldwide live with lupus and ~18 million with rheumatoid arthritis; tens of millions more carry other systemic autoimmune diseases.
IN HUMAN TRIALS
88/ 100
TO BROAD CURE

MILESTONEALKIVIA Phase 3 reported efgartigimod met the Week-52 primary endpoint in autoimmune myositis.

LATESTFDA approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA).

Disease-modifying therapies are in human clinical trials Β· Not medical advice.

CURRENT STATUS

Rheumatology is living through its most consequential shift since biologics. Engineered CD19 cell therapy is producing something the field has never seen: drug-free clinical and serological remission in refractory lupus, systemic sclerosis and myositis, with autoantibodies disappearing and patients coming off all immunosuppression. In parallel, anifrolumab validated type-I interferon blockade in lupus, JAK inhibitors deliver low-disease-activity remission in rheumatoid arthritis, and single-cell immune atlases are decoding which pathway β€” B-cell, interferon, or cytokine β€” actually drives each patient. The frontier has moved from "suppress the immune system indefinitely" to "reset tolerance and stop."

KEY BREAKTHROUGHS

CD19 CAR-T (CASTLE trial) β€” drug-free remission in refractory lupus, scleroderma, and myositis; patients off all immunosuppression

Anifrolumab (Saphnelo) β€” first type-I interferon receptor blocker approved for systemic lupus

JAK inhibitors (upadacitinib, others) delivering low-disease-activity remission in rheumatoid arthritis

Bispecific T-cell engagers (e.g., teclistamab-class) entering autoimmune trials as an off-the-shelf alternative to CAR-T

AI-COMPRESSED PIPELINE

AI TOOLS ACCELERATING CURES

Autoantibody Profiling AICAR-T Target SelectionSingle-cell Immune AtlasFlare Prediction Models

KEY ORGANIZATIONS

Bristol Myers SquibbKyverna TherapeuticsCabaletta BioAbbVieNovartis

KEY CLINICAL TRIALS

CD19 CAR-T for Refractory Lupus, Scleroderma & Myositis (CASTLE-class)

View

Kyverna / Cabaletta / academic (multi-program)

A single infusion of CD19-targeting CAR-T cells deeply depletes autoreactive B cells, aiming to "reboot" the immune system. Early basket studies report drug-free remission with no high-grade cytokine release syndrome.

πŸ‘₯ Phase 1/2 basket studies across SLE, systemic sclerosis, and myositisπŸ“ Germany, US β€” academic and sponsor sites

Bispecific T-cell Engagers in Autoimmune Disease

View

Multiple sponsors

Off-the-shelf antibodies that redirect T cells to destroy autoreactive B cells without manufacturing patient-specific cells β€” aiming to make the CAR-T "immune reset" faster and more scalable.

πŸ‘₯ Early-phase across lupus and rheumatoid arthritisπŸ“ US, EU β€” multicenter

TIMELINE ESTIMATE

RA low-disease-activity remission: available now. CD19 cell-therapy drug-free remission for severe lupus/scleroderma: 2–5 years to broader access. Broad autoimmune cure: 5–10 years.

EXPLORE FULL CURE PROTOCOL